Marshall R. Urist and the discovery of bone morphogenetic proteins

Grgurević, Lovorka; Pećina, Marko; Vukičević, Slobodan

doi:10.1007/s00264-017-3402-9

Cited by 32 publications

(17 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 1965, Marshall Urist demonstrated for the first time that demineralized bone has capacity to induce new bone when implanted at ectopic sites, which he described as Bbone formation by auto induction^ [12,13]. Reddi has shown that implantation of demineralized bone matrix induces a cascade of cellular events involving mesenchymal cell recruitment, proliferation, and differentiation into cartilage-forming cells.…”

Section: Bone Morphogenetic Proteinsmentioning

confidence: 99%

Bone morphogenetic proteins in fracture repair

Dumić-Čule

Perić

Kucko

et al. 2018

International Orthopaedics (SICOT)

Self Cite

View full text Add to dashboard Cite

Bone fractures represent a significant medical morbidity among aged population with osteoporosis. Bone morphogenetic proteins (BMPs) are suggested to have therapeutic potential to enhance fracture healing in such patients. Though BMP-mediated fracture healing has been well-documented in preclinical models, there has been no clinical study that demonstrated unequivocally that indeed a BMP when presented with an appropriate scaffold could provide basis for robust outcome for delayed or non-union diaphyseal bone fractures. This review presents a comprehensive insight towards the existing knowledge on the role of BMP signaling in bone formation and maintenance. Also therapeutic options based on BMP biology are discussed.A novel osteoinductive autologous bone graft substitute (ABGS) aimed to accelerate bone regeneration was developed and is currently being tested in the clinical setting. It comprises of a biologically compatible autologous carrier made from the patient's peripheral blood (autologous blood coagulum, ABC) and of rhBMP6 as an active ingredient. Such formulation circumvents the use of animal-derived materials, significantly limits inflammatory processes common in commercial bone devices and renders the carrier flexible, malleable, and injectable ensuring the ease of use. The ongoing clinical trials result will provide more detailed insights into the safety, tolerability, pharmacokinetics, and bone healing effects in humans and potentially provide novel and safe therapeutic options for bone repair.

show abstract

Section: Bone Morphogenetic Proteinsmentioning

confidence: 99%

Bone morphogenetic proteins in fracture repair

Dumić-Čule

Perić

Kucko

et al. 2018

International Orthopaedics (SICOT)

Self Cite

View full text Add to dashboard Cite

show abstract

“…The preparation process included debridement of adherent soft tissues and removal of blood and lipids. Then, DBM was prepared by modified Urist method [ 64 ] and lyophilized for later use. In primary grinding, freeze‐dried DBM was grinded with zirconia balls with a diameter of 1.5 cm in grinding mill (CryoMill, Tetsch, Germany) 5 min at the speed of 30 per min.…”

Section: Methodsmentioning

confidence: 99%

In Vitro and In Vivo Study of a Novel Nanoscale Demineralized Bone Matrix Coated PCL/β‐TCP Scaffold for Bone Regeneration

Yuan

Wang

Zhao

et al. 2020

Macromolecular Bioscience

View full text Add to dashboard Cite

Bone defects remains a challenge for surgeons. Bone graft scaffold can fill the defect and enhance the bone regeneration. Demineralized bone matrix (DBM) is an allogeneic bone graft substitute, which can only be used as a filling material rather than a structural bone graft. Coating of the scaffolds with nanoscale DBM may enhance the osteoinductivity or osteoconductivity. Herein the lyophilization method is presented to coat the nano‐DBM on surface of the porous polycaprolactone (PCL)/β‐tricalcium phosphate (β‐TCP) scaffolds fabricated by 3D printing technology. The morphology, elastic modulus, in vitro cell biocompatibility, and in vivo performance are investigated. Scanning electron microscope (SEM) shows DBM particle clusters with size of 200–500 nm are observed on scaffolds fibers after coating. MC3T3‐E1 cells on nano‐DBM coated PCL/β‐TCP scaffold show better activity than on PCL/β‐TCP scaffold. In vivo tests show better infiltration of new bone tissue in nano‐DBM coated PCL/β‐TCP scaffold than PCL/β‐TCP scaffold via the interface. These results show the presence of nano‐DBM coating on PCL/β‐TCP scaffold could enhance the attachment, proliferation, and viability of cells and benefit for the new bone formation surrounding and deep inside the scaffolds. Nano‐DBM could potentially be used as a new kind of biomaterial for bone defect treatment.

show abstract

“…He named this substance, the bone inductive principle, bone morphogenetic protein (BMP) and initiated an extensive and difficult search for these active protein molecules [2]. More than two decades later, advances in molecular biology by Dr. John Wozney's research team at the Genetic Institute described the first isolated extraction and recombinant form of BMP-2 in 1988 [3,4]. BMP-2 and BMP-7 have been shown to have the most bone forming potential out of the 15 BMPs identified and studied to date [5].…”

Section: Bone Morphogenetic Protein: Bmpmentioning

confidence: 99%

Class III Spine Grafts

Marx¹,

Lorio²

2021

Clinical Implementation of Bone Regeneration and Maintenance

View full text Add to dashboard Cite

This chapter is focused on the USFDA regulation and the related efficacy evidence of bone graft materials, especially Class III drug-device combination products for use in the spine. Nonstructural allograft and cellular allograft products that do not rely on the metabolic activity of living cells are HCT/P products, which require no premarket review for safety and efficacy. Synthetic bone grafts and demineralized bone matrices (DBMs) fall under Class II and require a 510(k) for market clearance, generally on the basis of an animal study. Drug-device combination bone grafts are Class III and require an investigational device exemption (IDE) clinical trial followed by a premarket approval (PMA) application with the FDA to review safety and effectiveness. Currently, there are only two PMA-supported Class III drug-device bone graft substitutes with Level I data that demonstrate equivalence to autograft for safety and effectiveness in spine: Infuse ® (rhBMP-2) and i-FACTOR (P-15 peptide). Both of these products have been shown to be effective autograft replacement options, vs. the other technologies, which are autograft extenders. The OP-1 Implant (rhBMP-7) was marketed for a period of time, but it has been removed from the market. This chapter will discuss these products along with their supporting clinical data.

show abstract

Marshall R. Urist and the discovery of bone morphogenetic proteins

Cited by 32 publications

References 36 publications

Bone morphogenetic proteins in fracture repair

Bone morphogenetic proteins in fracture repair

In Vitro and In Vivo Study of a Novel Nanoscale Demineralized Bone Matrix Coated PCL/β‐TCP Scaffold for Bone Regeneration

Class III Spine Grafts

Contact Info

Product

Resources

About